公开(公告)号：US11613755B2

公开(公告)日：2023-03-28

申请号：US17132793

申请日：2020-12-23

Applicant: Industrial Technology Research Institute

Inventor： Ping-Fu Cheng ,  Ya-Ling Chiu ,  Kang-Li Wang ,  Po-Yen Lin ,  Shih-Ta Chen ,  Tseng-Huang Liu ,  Pei-Shin Jiang

IPC: C12N15/115 ,  A61K47/54 ,  A61P35/00 ,  A61K9/00 ,  C12N15/113

Abstract: A nucleic acid-drug complex is provided in the present disclosure, which includes a nucleic acid sequence of an anti-PD-L1 aptamer and a CpG oligonucleotide sequence capable of activating TLR9, in which the CpG oligonucleotide sequence consists of a first fragment and a second fragment, and the nucleic acid sequence of the anti-PD-L1 aptamer is inserted between the first fragment and the second fragment.

公开(公告)号：US20240189243A1

公开(公告)日：2024-06-13

申请号：US18507536

申请日：2023-11-13

Applicant: Industrial Technology Research Institute

Inventor： Felice Cheng ,  Ping-Fu Cheng ,  Jenn-Tsang Hwang ,  Chih-Wei Fu ,  Ku-Feng Lin ,  Ya-Ling Chiu ,  Jheng-Sian Li ,  Kang-Li Wang ,  Siou-Han Chang ,  Chia-Yu Fan

IPC: A61K9/51 ,  A61K31/7105 ,  A61K31/711 ,  A61K47/28 ,  C07F9/09 ,  C07F9/535 ,  C07F9/6509 ,  C07F9/6512

CPC classification number: A61K9/5123 ,  A61K31/7105 ,  A61K31/711 ,  A61K47/28 ,  C07F9/091 ,  C07F9/535 ,  C07F9/650952 ,  C07F9/6512

Abstract: A lipid compound or a derivative thereof and a pharmaceutical composition employing the same are provided. The lipid compound has a structure represented by Formula (I):






wherein Z1, Z2, Z3 and Z4 are as disclosed in the specification.

公开(公告)号：US10398647B2

公开(公告)日：2019-09-03

申请号：US15788920

申请日：2017-10-20

Applicant: Industrial Technology Research Institute

Inventor： Wen-Hsuan Chiang ,  Yu-Wen Lo ,  Felice Cheng ,  Maggie Lu ,  Ya-Ling Chiu

IPC: A61K9/06 ,  A61K47/10 ,  A61K47/34 ,  A61K31/704 ,  A61K38/38 ,  A61K38/17 ,  C07K16/32 ,  A61K39/395 ,  A61K38/26 ,  A61K33/30 ,  A61K47/42 ,  A61K39/00 ,  A61K9/00

Abstract: A hydrogel composition is provided. The hydrogel composition includes polyglutamic acid (PGA) containing maleimide groups, and polyethylene glycol (PEG) containing terminal thiol groups, wherein the hydrogel composition has a pH value ranging from 4.0 to 6.5. A drug delivery system is also provided. The drug delivery system includes the above-mentioned hydrogel composition, and a pharmaceutically active ingredient encapsulated in the hydrogel composition.